Access cutting-edge multiple myeloma treatment through this clinical trial at a research site in Guilford. Study-provided care at no cost to qualified participants.
Access multiple myeloma specialists in Guilford at no cost
This study follows strict safety protocols and ethical guidelines
All study-related multiple myeloma treatment provided free
This phase II trial compares the combination of selinexor, daratumumab and hyaluronidase-fihj (daratumumab), velcade (bortezomib), and dexamethasone (Dara-SVD) to the usual treatment of daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVD) in treating patients with high-risk newly diagnosed multiple myeloma. Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may keep cancer cells from growin
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this multiple myeloma clinical trial in Guilford, CT
If you're searching for multiple myeloma treatment options in Guilford, CT, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Guilford research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.